Home About us Contact
|
Home About us Contact | ||
|
|
||
Nonhuman Primate Models (nonhuman + primate_models)
Selected Abstracts22nd Annual Symposium on Nonhuman Primate Models for AIDS November 3 , 6, 2004 San Antonio, TXJOURNAL OF MEDICAL PRIMATOLOGY, Issue 5-6 2005John L. VandeBerg Ph.D. First page of article [source] 20th Annual Symposium on Nonhuman Primate Models for AIDSJOURNAL OF MEDICAL PRIMATOLOGY, Issue 4-5 20032002 Monterey, September First page of article [source] 19th Annual Symposium on Nonhuman Primate Models for AIDS:JOURNAL OF MEDICAL PRIMATOLOGY, Issue 4-5 2002Monterey, September 8-1 [source] Nonhuman Primate Models of Women's Health, Guest Edited by Carol A. Shively and Thomas B. ClarksonAMERICAN JOURNAL OF PRIMATOLOGY, Issue 9 2009Paul A. Garber Executive Editor No abstract is available for this article. [source] Gene therapy approaches for Parkinson's diseaseJOURNAL OF NEUROCHEMISTRY, Issue 2003P. Aebischer The CNS delivery of glial cell line-derived neurotrophic factor (GDNF) for the treatment of Parkinson's disease constitutes one of the more promising clinical applications of neurotrophic factors. Crucial for clinical application will be the ability to deliver GDNF within the target structures, i.e. striatum and/or substantia nigra. We are developing both in vivo and ex vivo gene therapy approaches to reach this goal. We have shown in rodents that both lentiviral vectors coding for GDNF and polymer encapsulated cells genetically engineered to release GDNF are able to protect nigral dopaminergic neurons against various insults including axotomy and neurotoxins such as 6-hydroxydopamine. Even more important for clinical application is the ability to scale-up the technology to nonhuman primate application. Neurorestorative and/or neuroprotective properties of GDNF expression were demonstrated with both methods in various nonhuman primate models. [source] Engraftment of Adult Porcine Islet Xenografts in Diabetic Nonhuman Primates Through Targeting of Costimulation PathwaysAMERICAN JOURNAL OF TRANSPLANTATION, Issue 10 2007K. Cardona Recent advances in human allogeneic islet transplantation have established ,-cell replacement therapy as a potentially viable treatment option for individuals afflicted with Type 1 diabetes. Two recent successes, one involving neonatal porcine islet xenografts transplanted into diabetic rhesus macaques treated with a costimulation blockade-based regimen and the other involving diabetic cynomolgus monkeys transplanted with adult porcine islet xenografts treated with an alternative multidrug immunosuppressive regimen have demonstrated the feasibility of porcine islet xenotransplantation in nonhuman primate models. In the current study, we assessed whether transplantation of adult porcine islet xenografts into pancreatectomized macaques, under the cover of a costimulation blockade-based immunosuppressive regimen (CD28 and CD154 blockade), could correct hyperglycemia. Our findings suggest that the adult porcine islets transplanted into rhesus macaques receiving a costimulation blockade-based regimen are not uniformly subject to hyperacute rejection, can engraft (2/5 recipients), and have the potential to provide sustained normoglycemia. These results provide further evidence to suggest that porcine islet xenotransplantation may be an attainable strategy to alleviate the islet supply crisis that is one of the principal obstacles to large-scale application of islet replacement therapy in the treatment of Type 1 diabetes. [source] | |||||||||||||